Subtype
Rectal Neoplasm
CI-CAN-00006564Explore in graph →
Non-malignant433 active trials1 approved drugs5 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006564Explore in graph →
Clinical trials
1,772 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03770689 | Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer | completed | Phase 1 / Phase 2 | 19 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 2 | Mar 21, 2023 | clinicaltrials |
| NCT02399813 | A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal | completed | Phase 2 | 36 | Advaxis, Inc.INDUSTRY | 1 | Mar 20, 2023 | clinicaltrials |
| NCT03299660 | Avelumab With Chemoradiation in Locally Advanced Rectal Cancer | completed | Phase 2 | 37 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT03043729 | mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer | completed | Phase 2 | 119 | AIO-Studien-gGmbHOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT04009876 | A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal Cancer | completed | Phase 2 | 30 | Fundación de investigación HMOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT05622357 | Prospective Study of Short Course Radiation Therapy Followed by Neoadjuvant Chemotherapy and Surgery in Locally Advanced Rectal Cancer | completed | Phase 2 | 51 | National Cancer Institute, EgyptOTHER | 1 | Nov 18, 2022 | clinicaltrials |
| NCT02569645 | Rosuvastatin in the Treatment of Rectal Cancer | completed | Phase 2 | 45 | AHS Cancer Control AlbertaOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT03666442 | Early Evaluation of Chemosensitivity for Low/Intermediated-risk Mid-low Stage II/III Rectal Cancer | completed | Phase 2 | 61 | West China HospitalOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT03102047 | Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer | completed | Phase 2 | 45 | NSABP Foundation IncNETWORK | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03000374 | Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery(PIER) | completed | Phase 2 | 34 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT05274945 | Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer | completed | Phase 2 | 58 | Alexandria UniversityOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT00308516 | 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer | completed | Phase 2 | 66 | SCRI Development Innovations, LLCOTHER | 1 | Dec 10, 2021 | clinicaltrials |
| NCT02992886 | Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly | completed | Phase 2 | 68 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT00040599 | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer | completed | Phase 1 / Phase 2 | 72 | Gilead SciencesINDUSTRY | 5 | Aug 19, 2021 | clinicaltrials |
| NCT00041652 | Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer | completed | Phase 1 / Phase 2 | 30 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT02864849 | Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer | completed | Phase 2 | 81 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jul 23, 2021 | clinicaltrials |
| NCT02393755 | Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT01902953 | Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC) | completed | Phase 2 | 16 | Maimonides Medical CenterOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT02340949 | Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer(RIA) | completed | Phase 2 | 180 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 0 | May 3, 2021 | clinicaltrials |
| NCT02217020 | Neoadjuvant FOLFOXIRI Chemotherapy Alone for Locally Advanced Rectal Cancer(FORTUNE) | completed | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Apr 14, 2021 | clinicaltrials |
| NCT04795180 | Pilot Randomized Evaluation of Butyrate Irrigation Before Ileostomy Closure on the Colonic Mucosa in Rectal Cancer Patients (BUTYCLO)(BUTYCLO) | completed | Phase 2 | 45 | Institut d'Investigació Biomèdica de Girona Dr. Josep TruetaOTHER | 1 | Mar 12, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT02641691 | Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum(NORMAL-R) | completed | Phase 2 | 20 | Washington University School of MedicineOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT01481545 | Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer(BRANCH) | completed | Phase 2 | 62 | National Cancer Institute, NaplesOTHER | 0 | Feb 3, 2021 | clinicaltrials |
| NCT03443661 | Neoadjuvant Triplet Chemotherapy Regimen in Patients With Locally Advanced Rectal Cancer | completed | Phase 2 | 50 | Aiping ZhouUNKNOWN | 1 | Feb 1, 2021 | clinicaltrials |
| NCT01397305 | An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer | completed | Phase 1 / Phase 2 | 24 | Isofol Medical ABINDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT01363843 | Complete Neoadjuvant Treatment for REctal Cancer (CONTRE) | completed | Phase 2 | 39 | William Sikov MDOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT01674309 | First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis | completed | Phase 2 | 65 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT01650428 | Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery(BACCHUS) | completed | Phase 2 | 20 | University College, LondonOTHER | 1 | Oct 7, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT03053544 | Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer | completed | Phase 2 | 15 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 27, 2019 | clinicaltrials |
| NCT01802320 | Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 20, 2019 | clinicaltrials |
| NCT01111604 | A Study of Ramucirumab or Icrucumab in Colorectal Cancer | completed | Phase 2 | 158 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 6, 2019 | clinicaltrials |
| NCT02973672 | Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas | completed | Phase 1 / Phase 2 | 75 | SurgimabINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT00828672 | Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer(AXEBEAM) | completed | Phase 2 | 84 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 10, 2019 | clinicaltrials |
| NCT01985763 | Genistein in Treatment of Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 13 | Sofya PintovaOTHER | 1 | May 10, 2019 | clinicaltrials |
| NCT01206530 | FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer | completed | Phase 1 / Phase 2 | 50 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 18, 2019 | clinicaltrials |
| NCT00645710 | Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery | completed | Phase 1 / Phase 2 | 16 | City of Hope Medical CenterOTHER | 1 | Mar 28, 2019 | clinicaltrials |
| NCT00321685 | Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2019 | clinicaltrials |
| NCT01717391 | [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers | completed | Phase 2 | 36 | John M. BuattiOTHER | 1 | Mar 26, 2019 | clinicaltrials |
| NCT00409994 | Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer | completed | Phase 1 / Phase 2 | 44 | Maastricht Radiation OncologyOTHER | 1 | Mar 18, 2019 | clinicaltrials |
| NCT00257322 | Cellular Immune Augmentation in Colon and Rectal Cancer | completed | Phase 2 | 20 | University of California, IrvineOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00094809 | Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer | completed | Phase 2 | 252 | AmgenINDUSTRY | 0 | Oct 17, 2018 | clinicaltrials |
| NCT00418938 | SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial | completed | Phase 2 | 266 | AmgenINDUSTRY | 0 | Oct 17, 2018 | clinicaltrials |
| NCT03085992 | Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer(TRUST) | completed | Phase 2 | 49 | Azienda Ospedaliero, Universitaria PisanaOTHER | 1 | Mar 14, 2018 | clinicaltrials |
| NCT02353858 | Preoperative Radiochemotherapy With Hyperthermia for Locally Advanced Rectal Cancer(HT01) | completed | Phase 2 | 78 | University Hospital TuebingenOTHER | 1 | Feb 13, 2018 | clinicaltrials |
| NCT01589471 | The Value of Botox-A for Management of Low Anterior Resection Syndrome | completed | Phase 2 | 23 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Feb 12, 2018 | clinicaltrials |
| NCT03428529 | Capecitabine Versus Bolus 5-Fu Associated to Radiotherapy as Neoadjuvant Treatment for Rectal Cancer.(INCAGI004) | completed | Phase 2 / Phase 3 | 63 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 0 | Feb 9, 2018 | clinicaltrials |
| NCT00972881 | Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer(EXCITE) | completed | Phase 1 / Phase 2 | 82 | University College, LondonOTHER | 1 | Oct 25, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Mar 21, 2023source: clinicaltrials